Table 1.
All of the miRNAs associated with Cisplatin (CDDP) resistance in head and neck tumors
| STUDY | YEAR | TUMOR TYPE | GENE | TARGET | SAMPLES | RESULTS |
|---|---|---|---|---|---|---|
| Song (35) | 2021 | LSCC | miR-497-5p | SEPT2 |
38 patients Hep2, TU212, TU686, SCC-2 and 16HBE cell lines |
Increased CDDP sensitivity |
| Lin (46) | 2016 | OSCC | miR-203 | PIK3CA |
10 patients Tca8113 cell line |
Increased CDDP Sensitivity |
| Wang (50) | 2017 | NPC | ANRIL | let-7a |
35 patients CNE1, CNE2, S18, HONE1, and 5–8 F cell lines |
Increased CDDP resistance |
| Lin (51) | 2020 | NPC | miR-454-3p | c-Met |
96 patients C666-1 and HNE1 cell lines |
Increased CDDP sensitivity |
| Zheng (53) | 2015 | TSCC | miR-24 | PTEN |
79 patients NHOK, UMI, UM2, Cal27, SCCI, SCC2, SCC9, SCC15 and SCC25 cell lines |
Increased CDDP resistance |
| Sheng (54) | 2022 | HNSCC | miR-21 | PTEN |
30 patients UMSCC-1, UMSCC-10 A, UMSCC-22B, Cal33, UPCI-4B, UPCI-15B, 1483, and 686LN cell lines |
Increased CDDP resistance |
| Zhen (56) | 2017 | NPC | miR-374a | CCND1 |
239 patients SUNE1, 5 − 8 F, shPDCD4-SUNE1, shPDCD4-HONE1 and PDCD4-overexpressed 5 − 8 F cell lines |
Increased CDDP sensitivity |
| Liu (57) | 2017 | OSCC | miR-21 | PTEN and PDCD4 | HSC-3 and SCC-9 cell lines | Increased CDDP resistance |
| Shi (62) | 2016 | NPC | miR-26b | JAG1 |
66 patients CNE2, HNE1, HNE1/DDP and CNE2/DDP cell lines |
Increased CDDP sensitivity |
| Yuan (66) | 2018 | laryngeal carcinoma | miR-320a | RBPJ |
24 patients HEp-2 cell line |
Increased CDDP sensitivity |
| Zeng (72) | 2021 | OSCC | miR-4786-3p | SELENBP1 | Cal27, HSC3, SCC25, HOK and SCC9 cell lines | Increased CDDP resistance |
| Zhuang (75) | 2017 | oral cancer | miR-218 | PPP2R5A |
61 patients UM1, UM2, Cal27, MD1386Ln and Tca8113 cell lines |
Increased CDDP resistance |
| Wang (77) | 2017 | NPC | miR-183 | MTA1 |
29 patients C666-1, CNE1, CNE2, HONE1, and 5-8 F cell lines |
Increased CDDP sensitivity. |
| Shibata (78) | 2022 | HNSCC | miR-766-3p | NR3C2 |
12 patients CAL27 and FaDu cell lines |
Increased CDDP resistance |
| Yuan (80) | 2019 | laryngeal carcinoma | miR-425-5p | PTCH1 |
24 patients Hep-2 Hep-2/R Cell lines |
Increased CDDP sensitivity |
| Bissey (96) | 2020 | NPC | miR-34c | SOX4 |
246 patients C666–1, NP69, NP460, and HEK 293T cell lines |
Increased CDDP sensitivity |
| Chen (97) | 2020 | OSCC | miR-132 | TGF-β1 |
37 patients SCC-9 and CAL-27 cell lines |
Increased CDDP sensitivity |
| Gu (100) | 2018 | TSCC | miR-22 | KAT6B |
28 patients CAL27, SCC9, and HCT 116 cell lines |
Increased CDDP sensitivity |
| Lin (102) | 2021 | NPC | miR-515-5p | IL-25 |
138 patients HK-1 and CNE-1 cell lines |
Increased CDDP sensitivity |
| Liu (109) | 2015 | ACC | miR-101-3p | Pim-1 |
30 patients SACC-LM and SACC-83 cell lines |
Increased CDDP sensitivity |
| Wang (110) | 2019 | OSCC | miR-214-3p | PIM-1 |
31 patients NHOK, OSCC, TSCCA, CAL-27, SCC-9, and Tca8113 cell lines |
Increased CDDP sensitivity |
| Tian (116) | 2017 | laryngeal cancer | miR-26b | ATF2 | Hep-2 and Hep-2/R cell lines | Increased CDDP sensitivity. |
| Fan (123) | 2015 | TSCC | miR-483-5p | FIS1 |
108 patients CAL27 and SCC9 cell lines |
Increased CDDP resistance |
| Chen (130) | 2015 | NPC | miR-125a and miR-125b | p53 mRNA |
10 patients TW03, CNE-1, CNE-2 and NP69 |
Increased CDDP resistance |
| Wang (134) | 2020 | OSCC | miR-421 | MEIS2 |
45 patients NHOK, CAL-27, Tca8113, SCC-9, and TSCCA |
Increased CDDP sensitivity |
| Liu (138) | 2016 | laryngeal carcinoma | miR-125a | HAX-1 |
30 patients Hep-2 cell line |
Increased CDDP sensitivity. |
| Lin (140) | 2020 | LSCC | miR-936 | GPR78 |
25 patients Hep-2, 16HBE, HEK293T and KB-3-1 cell lines |
Increased CDDP sensitivity |
| Chen (148) | 2021 | LSCC | miR-107 | HMGB1 | 30 patients | Increased CDDP sensitivity |
| Zhao (149) | 2020 | NPC | miR-1278 | ATG2B |
90 patients CNE-1, CNE-2, C666-1, 5–8 F and HONE-1 cell lines |
Increased CDDP sensitivity |
| Feng (150) | 2021 | laryngeal carcinoma | miR-376a | ATG2A |
30 patients SNU46 and M4E cell lines |
Increased CDDP sensitivity |
| Hao (155) | 2020 | NPC | miR-205 | HER3 | CNE1, CNE2, SUNE1 and HK1 cell lines | Increased CDDP sensitivity |
| Zhang (160) | 2019 | NPC | miR-205-5p | PTEN | HNE1 and HNE1/DDP cell lines | Increased CDDP resistance |
| Peng (162) | 2015 | TSCC | miR-23a | Twist1 | SCC-4 and Tca8113 cell lines | Increased CDDP resistance |
| Wang (163) | 2017 | TSCC | miR-15b | TRIM14 | SCC25 and SCC25-res cell lines | Increased CDDP sensitivity |
| Li (167) | 2021 | NPC | miR-98 | PBX3 |
40 patients NP-69 and 5-8 F cell lines |
Increased CDDP sensitivity |
| Sun (170) | 2012 | TSCC | miR-200b and miR-15b | BMI1 | CAL27, SCC25, CAL27-res and SCC25-res cell lines | Increased CDDP sensitivity |
| Yang (174) | 2020 | NPC | miR-200c | c-myc |
149 patients CNE1, CNE2, 5–8 F cell lines |
Increased CDDP sensitivity |
| Yang (178) | 2021 | HNC | miR-136-5p | ROCK1 | FaDu and FD-LSC-1 cell lines | Increased CDDP sensitivity |
| Zhang (181) | 2018 | TSCC | miR-211-5p | Ezrin |
102 patients CAL27, SCC9, CAL27-res and SCC9-res cell lines |
Increased CDDP sensitivity. |
| Cao (182) | 2020 | NPC | miR-218-5p | GDPD5 |
CNE1, SUNE1, HNE1, and 5-8 F Cell lines |
Increased CDDP sensitivity |
| Shan (186) | 2015 | TSCC | miR-338 | HIF-1α |
5 patients NP69, CNE2, CNE1, 5-8 F and 6-10B cell lines |
Increased CDDP sensitivity |
| Yuan (188) | 2021 | NPC | miR-454 | USP47 |
50 patients 5-8 F and SUNE-1 cell lines |
Increased CDDP sensitivity |
| Song (190) | 2021 | OSCC | miR-619-5p | ATXN3 |
40 patients HOK, Leuk-1, HN4, HN6, CAL27, and UMSCC38 cell lines |
Increased CDDP sensitivity |
| Yuan (195) | 2017 | NPC | miR-125b | Bcl-2 and MDR1 | CNE2 cell line | Increased CDDP sensitivity |
| Gobin (196) | 2023 | LSCC | miR-9 | ABCC1 | UM-SCC-12 and UM-SCC-10 A cell lines | Increased CDDP sensitivity |
| Gao (197) | 2022 | OSCC | miR-188-3p | ABCB1 |
60 patients SCC-4, SCC-9, CAL-27, UM1, and UM2 cell lines |
Increased CDDP sensitivity |